Houston, TX — November 5, 2025 — Leads & Copy —
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) will present its abstract on an adaptive Phase 2/3 study for PCS499 in patients with Focal Segmental Glomerulosclerosis (FSGS) at the American Society of Nephrology (ASN) Kidney Week 2025, November 5–9, in Houston, Texas. The poster, FR-PO0829, will be part of the session “Glomerular Clinical Trials: From Data to Impact” on Friday, November 7, from 10:00 a.m. to 12:00 p.m. Central Time.
PCS499 is an analog of a metabolite of pentoxifylline (PTX) and has demonstrated a favorable safety profile over PTX. The adaptive Phase 2/3 design that Processa will be discussing with FDA later this year and presenting at ASN aims to optimize dosing and accelerate the path toward regulatory approval.
According to David Young, Pharm.D., Ph.D., President of Research and Development at Processa Pharmaceuticals, the company is honored to present its PCS499 program at ASN Kidney Week.
Focal Segmental Glomerulosclerosis is a rare, progressive kidney disease characterized by scarring in the kidney’s filtering units, often leading to end-stage renal disease. There are currently no FDA-approved therapies specifically indicated for FSGS.
For more information, visit www.processapharma.com.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
PCSA@redchip.com
Source: Processa Pharmaceuticals, Inc.
Source: Processa Pharmaceuticals, Inc.
